Lineage Cell Therapeutics, Inc. Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31)
Lineage Cell Therapeutics, Inc. (LCTX) reported Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31) of $2.33 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-17.
Discontinued › Income Statement › Other Income
us-gaap:EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountries · last filed 2014-03-17
- Lineage Cell Therapeutics, Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2013 was $2.33M, a 68.02% increase from fiscal 2012.
- Lineage Cell Therapeutics, Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2012 was $1.39M, a 0.82% increase from fiscal 2011.
- Lineage Cell Therapeutics, Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2011 was $1.37M, a 246.35% increase from fiscal 2010.
- Lineage Cell Therapeutics, Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2010 was $396.81K.
| Period end | Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31) 12 month |
|---|---|
| 2013-12-31 | $2.33M 10-K · filed 2014-03-17 |
| 2012-12-31 | $1.39M 10-K · filed 2014-03-17 |
| 2011-12-31 | $1.37M 10-K · filed 2014-03-17 |
| 2010-12-31 | $396.81K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |